证券日报网讯 普洛药业11月25日在互动平台回答投资者提问时表示，公司丁二磺酸腺苷蛋氨酸肠溶片 于2024年11月获批，目前在京津冀"3+N"联盟和广东联盟中已中标，正处于快速拓展市场中。 （编辑 袁冠琳） ...

普洛药业股份有限公司 关于第一期员工持股计划存续期即将届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000739 证券简称：普洛药业 公告编号：2025-72 4、2024 年 3 月 6 日，公司召开第九届董事会第四次会议，审议通过了《关 于公司第一期员工持股计划存续期展期的议案》，同意将公司第一期员工持股计 划存续期展期 24 个月，即存续期展期至 2026 年 5 月 28 日。 具体内容详见公司分别于 2019 年 6 月 12 日、2020 年 6 月 11 日、2022 年 3 月 10 日、2024 年 3 月 8 日刊登在《证券时报》和巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。 5、截至本公告日，公司第一期员工持股计划通过集中竞价交易方式累计减 持 11,100,000 股；尚持有公司股份 21,564,016 股，占公司目前总股本的 1.86%。 本次员工持股计划持有公司股份均未出现或用于抵押、质押、担保等情形。 普洛药业股份有限公司(以下简称"公司")分别于 2019 年 5 月 10 ...

普洛药业（000739.SZ）11月25日在投资者互动平台表示，医美化妆品原料业务是公司重点培育的发展 方向，目前正处于新产品和新客户开发阶段，预计未来几年该业务市场规模有望实现较快的增长。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：2024年11月4日，普洛药业正式成立医美及化妆品事业 部，并以"助力美好生活"为使命，请问成立一年来医美事业部发展如何？开发了哪些产品和客户？事业 部人员和市场开拓规模怎么样？ ...

（文章来源：每日经济新闻） 普洛药业（000739.SZ）11月25日在投资者互动平台表示，公司丁二磺酸腺苷蛋氨酸肠溶片于2024年11 月获批，目前在京津冀"3+N"联盟和广东联盟中已中标，正处于快速拓展市场中。 每经AI快讯，有投资者在投资者互动平台提问：公司丁二磺酸苷蛋氨酸肠溶片，因为是天然生理活性 分子，药理作用机制明确，安全性高，临床疗效好，作为值得推广的首选肝病治疗药物，获批上市一年 多，市场推广和销售情况如何？ ...

格隆汇11月25日丨普洛药业(000739.SZ)在投资者互动平台表示，医美化妆品原料业务是公司重点培育 的发展方向，目前正处于新产品和新客户开发阶段，预计未来几年该业务市场规模有望实现较快的增 长。 ...

格隆汇11月25日丨普洛药业(000739.SZ)在投资者互动平台表示，医美化妆品原料业务是公司重点培育 的发展方向，目前正处于新产品和新客户开发阶段，预计未来几年该业务市场规模有望实现较快的增 长。 ...

丨2025年11月25日 星期二丨 11月24日，"SINOVAC"微信公众号发文称，国家药品监督管理局批准了北京科兴控股（集团）有限公 司旗下科兴中维与大连科兴联合研制的重组带状疱疹疫苗（CHO细胞）的临床试验申请，该疫苗用于 40岁及以上人群预防带状疱疹。 点评：目前国内共有两款带状疱疹疫苗获批，分别来自跨国药企葛兰素史克、中国公司百克生物，但这 两款产品的销售情况均不乐观。面对公众的低接种意愿，价格高昂的自费疫苗的研发及商业化如何开 展，疫苗公司需要思考这个问题。 NO.4阿斯利康宣布今年第四项美国重大制造投资 近日，英国药企阿斯利康宣布计划投资20亿美元，扩大其在马里兰州长期的制造业务，这是公司今年宣 布的第四项美国重大制造业投资。 NO.1和铂医药宣布与阿斯利康深化推进全球战略合作 11月24日，和铂医药发布公告，称将更新与深化推进其与阿斯利康于今年3月建立的全球战略合作。在 本次合作中，双方将基于各自专业技术知识，共同发现和开发包括抗体偶联药物（ADC）和T细胞衔接 器（TCE）在内的新一代生物疗法。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研 发项目，并获得这些项目的授权许可选择权 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 公司一直高度重视药品研发，并非常注重药品研发、制造及销售等环节的质量、安全和合规。但是药品 的生产和销售可能会受到政策法规、市场环境变化等不确定性因素的影响。敬请广大投资者谨慎决策， 注意防范投资风险。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛巨泰药业有限公司收到国家药品 监督管理局（以下简称"药监局"）签发的头孢地尼干混悬剂（1.5g；3.0g）《药品注册证书》。现将有 关情况公告如下： 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。 二、药品其他相关情况 头孢地尼干混悬剂，属于第三代口服头孢菌素类抗生素，适用于治疗由下列条件下的指定微生物的敏感 菌株引起的轻度至中度感染的儿童患者。急性细菌性中耳炎由流感嗜血杆菌（包括产生β-内酰胺酶的菌 株）、肺炎链球菌（仅对青霉素敏感的菌株）和卡他莫拉菌（包括产生β-内酰胺酶的菌株）引起。咽 炎/扁桃体炎由化脓性链球菌引起。单纯性皮肤和皮肤组织感染由金黄色葡萄球菌（包括产生 ...

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the last 30 days include United Imaging Healthcare, Lens Technology, Aibo Medical, Sanhua Intelligent Control, and Zhaoyi Innovation [2][13] - In the last 5 days, the most popular companies for institutional research include Ninebot Company-WD, Rongbai Technology, Lens Technology, Yintong Intelligent Control, and Yinglian Co., Ltd [2][15] - Among the top twenty companies in the last 30 days, 19 companies had 10 or more rating agencies involved, with significant profit growth expected for Jiao Cheng Ultrasound, Lanke Technology, and United Imaging Healthcare in Q1-Q3 of 2025 compared to the same period in 2024 [2][13][16] Group 2: Major Shareholder Increase in A-Share Listed Companies - From November 17 to November 21, 2025, five listed companies announced significant shareholder increases, with Changshu Bank increasing its shareholding by more than 1% of total equity, while Huangtai Liquor, Longlide, Fuguang Co., and Feiwo Technology planned to increase their holdings with an average of more than 1% of the market value on the announcement date [3][20] - From January 1 to November 21, 2025, a total of 295 companies announced significant shareholder increases, with 90 of them having 10 or more rating agencies involved. Among these, 23 companies had an average planned increase amount exceeding 1% of the market value on the announcement date, including Xianhe Co., Hubei Yihua, Xinji Energy, and Zhongju Gaoxin [5][22] Group 3: Share Buyback Situation in A-Share Listed Companies - From November 17 to November 21, 2025, 65 companies announced their buyback progress, with 16 companies having 10 or more rating agencies involved. Five companies had an average planned buyback amount exceeding 1% of the market value on the announcement date, with a focus on Jian Sheng Group, Trina Solar, and Prologis Pharmaceuticals [4][25] - From January 1 to November 21, 2025, a total of 1,805 companies announced their buyback progress, with 344 of them having 10 or more rating agencies involved. Among these, 88 companies had a significant buyback ratio, with two companies, Huaming Equipment and Prologis Pharmaceuticals, still in the board proposal stage [6][27]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]